Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Presentation TCT 2025

TCT 494: Cost-Effectiveness of SGLT2 Inhibitors, Statins, and GLP-1 Receptor Agonists for Cardiovascular Secondary Prevention: A Comparative Analysis

Presenter: Mehmet Cilingiroglu

October 28, 2025

Presentation TCT 2024

TCT 327: Efficacy of High-Dose Statins on the Prevention of Contrast-Induced Nephropathy After Cardiac Catheterization: Updated Systematic Review and Meta-Analysis

Presenter: Montaser Elkholy

October 30, 2024

Presentation TCT 2024

What Happens Next? Beyond Statins for Optimizing LDL-C Management After Coronary and Peripheral Intervention

Presenter: David Kwon

October 29, 2024

Presentation Controversies and Advances 2021

EPA Fish Oil: Who Should Receive It?

Presenter: Peter P. Toth

December 03, 2021

Presentation ACC 2017

EBBINGHAUS: A Cognitive Study of Patients Enrolled in the FOURIER Trial

Presenter: Robert Giugliano

March 19, 2017

Presentation ACC 2017

Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk

Presenter: Marc Sabatine

March 17, 2017

Presentation TCT 2015

Hyperlipidemic Therapy: From Statins to PCSK9 Inhibitors

Presenter: George D. Dangas, Paul A. Gurbel, Joshua W. Knowles

October 13, 2015

Presentation TCT 2014

Flash Debate: Statins for Contrast Nephropathy Prevention Ready for Prime Time? Con!

Presenter: Antonio L. Bartorelli, Somjot S. Brar, Roxana Mehran, Richard Solomon

September 16, 2014

Presentation

Preoperative Statins and Limb Salvage after Lower Extremity Revascularization in the Medicare Population

Presenter: Todd R. Vogel

December 11, 2013

Presentation TCT 2012

Do Statins and Other Therapies Alter Vulnerable Plaque Characteristics? Insights from Imaging

Presenter: Pedro Moreno

October 23, 2012

Advertisement

TCT 494: Cost-Effectiveness of SGLT2 Inhibitors, Statins, and GLP-1 Receptor Agonists for Cardiovascular Secondary Prevention: A Comparative Analysis

TCT 327: Efficacy of High-Dose Statins on the Prevention of Contrast-Induced Nephropathy After Cardiac Catheterization: Updated Systematic Review and Meta-Analysis

What Happens Next? Beyond Statins for Optimizing LDL-C Management After Coronary and Peripheral Intervention

EPA Fish Oil: Who Should Receive It?

EBBINGHAUS: A Cognitive Study of Patients Enrolled in the FOURIER Trial

Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk

Hyperlipidemic Therapy: From Statins to PCSK9 Inhibitors

Flash Debate: Statins for Contrast Nephropathy Prevention Ready for Prime Time? Con!

Preoperative Statins and Limb Salvage after Lower Extremity Revascularization in the Medicare Population

Do Statins and Other Therapies Alter Vulnerable Plaque Characteristics? Insights from Imaging

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content